Production (Stage)
Vaxil Bio Ltd.
VXLLD
$0.12
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -63.92% | -73.43% | -53.52% | -43.33% | 2.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.15% | -80.85% | -68.40% | -57.87% | -37.52% |
| Operating Income | 71.15% | 80.85% | 68.40% | 57.87% | 37.52% |
| Income Before Tax | 71.49% | 80.85% | 68.40% | 57.87% | 38.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.49% | 80.85% | 68.40% | 57.87% | 38.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.49% | 80.85% | 68.40% | 57.87% | 38.20% |
| EBIT | 71.15% | 80.85% | 68.40% | 57.87% | 37.52% |
| EBITDA | 106.87% | 99.76% | 78.38% | 58.06% | 36.52% |
| EPS Basic | 71.46% | 80.86% | 68.41% | 57.89% | 37.25% |
| Normalized Basic EPS | 72.87% | 80.85% | 68.39% | 57.83% | 36.45% |
| EPS Diluted | 71.46% | 80.86% | 68.41% | 57.89% | 37.25% |
| Normalized Diluted EPS | 72.87% | 80.85% | 68.39% | 57.83% | 36.45% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.99% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |